Glucagon-like peptide 1 (GLP-1)

Molecular Metabolism
30, 72-130
DOI: 10.1016/j.molmet.2019.09.010

Citation Report

#	Article	IF	Citations
1	Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue. Endocrinology, 2020, 161, .	1.4	15
2	Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells. Biomolecules, 2020, 10, 1404.	1.8	11
3	Acute postprandial effect of yacon syrup ingestion on appetite: A double blind randomized crossover clinical trial. Food Research International, 2020, 137, 109648.	2.9	7
4	Evaluation of an Amino Acid Mix on the Secretion of Gastrointestinal Peptides, Glucometabolic Homeostasis, and Appetite in Obese Adolescents Administered with a Fixed-Dose or ad Libitum Meal. Journal of Clinical Medicine, 2020, 9, 3054.	1.0	4
5	The role of obesity on chronic kidney disease development, progression, and cardiovascular complications. Advances in Biomarker Sciences and Technology, 2020, 2, 24-34.	0.8	15
6	Repositioning the Alpha Cell in Postprandial Metabolism. Endocrinology, 2020, 161, .	1.4	18
7	Understanding Dietary Intervention-Mediated Epigenetic Modifications in Metabolic Diseases. Frontiers in Genetics, 2020, 11, 590369.	1.1	19
8	Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3075-3087.	1.1	7
9	Mechanisms of muscle insulin resistance and the crossâ€talk with liver and adipose tissue. Physiological Reports, 2020, 8, e14607.	0.7	76
10	Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2020, 15, 379-394.	1.2	37
11	Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochemical Pharmacology, 2020, 180, 114150.	2.0	23
12	Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis. Cell Reports, 2020, 31, 107768.	2.9	18
13	The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. Frontiers in Endocrinology, 2020, 11, 599355.	1.5	12
14	Insights into the potential benefits of black soybean (Glycine maxL.) polyphenols in lifestyle diseases. Food and Function, 2020, 11, 7321-7339.	2.1	15
15	Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-ÎºB and MAPK pathways via GLP-1R. Biomedicine and Pharmacotherapy, 2020, 130, 110523.	2.5	23
16	Abdominal sepsis patients have a high incidence of chronic critical illness with dismal long-term outcomes. American Journal of Surgery, 2020, 220, 1467-1474.	0.9	17
17	Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E568-E578.	1.8	16
18	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimerâ€™s and Parkinsonâ€™s disease therapeutics. Biochemical Pharmacology, 2020, 180, 114187.	2.0	57

#	Article	IF	Citations
20	Intestinal NAPE-PLD contributes to short-term regulation of food intake via gut-to-brain axis. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E647-E657.	1.8	14
21	Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. Nutrients, 2020, 12, 3304.	1.7	21
22	Small-molecule GLP-1 secretagogs: challenges and recent advances. Drug Discovery Today, 2020, 25, 2023-2029.	3.2	5
23	The Neurotrophic Function of Glucagon-Like Peptide-1 Promotes Human Neuroblastoma Differentiation via the PI3K-AKT Axis. Biology, 2020, 9, 348.	1.3	9
24	Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes. Journal of Medicinal Chemistry, 2020, 63, 12595-12613.	2.9	13
25	Glucagon-like peptide-1, a matter of taste?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 763-775.	2.6	8
26	Nutrient consumption-dependent association of a glucagon-like peptide-1 receptor gene polymorphism with insulin secretion. Scientific Reports, 2020, 10, 16382.	1.6	5
27	Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. Current Obesity Reports, 2020, 9, 391-401.	3.5	9
28	Beneficial actions of a longâ€acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation. Diabetes, Obesity and Metabolism, 2020, 22, 2468-2478.	2.2	17
29	Baicalin-Copper Complex Modulates Gut Microbiota, Inflammatory Responses, and Hormone Secretion in DON-Challenged Piglets. Animals, 2020, 10, 1535.	1.0	13
30	Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade. Drug and Chemical Toxicology, 2022, 45, 1254-1263.	1.2	9
31	Effects of Dietary Phytoestrogens on Hormones throughout a Human Lifespan: A Review. Nutrients, 2020, 12, 2456.	1.7	90
32	Therapeutic potential of Î±7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 431-447.	2.6	24
33	Drug Delivery System in the Treatment of Diabetes Mellitus. Frontiers in Bioengineering and Biotechnology, 2020, 8, 880.	2.0	41
34	Circadian GLP-1 Secretion in Mice Is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis. Diabetes, 2020, 69, 2589-2602.	0.3	33
35	Hope in Hopeless Times: Gearing Up to Fight the Obesity Pandemic. Endocrinology, 2020, 161, .	1.4	2
36	Role of exendinâ€4 in the Gila monster: Further lessons regarding human oral glucagonâ€like peptideâ€1 therapy?. Diabetes, Obesity and Metabolism, 2020, 22, 2509-2511.	2.2	4
37	Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. Frontiers in Cell and Developmental Biology, 2020, 8, 602574.	1.8	51

#	Article	IF	Citations
38	GLP-1 receptors are involved in the GLP-1 (7â€“36) amide-induced modulation of glucose homoeostasis, emesis and feeding in Suncus murinus (house musk shrew). European Journal of Pharmacology, 2020, 888, 173528.	1.7	3
39	Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell and Bioscience, 2020, 10, 140.	2.1	26
40	Incretin Hormones and Type 2 Diabetesâ€"Mechanistic Insights and Therapeutic Approaches. Biology, 2020, 9, 473.	1.3	35
41	Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food. International Journal of Molecular Sciences, 2020, 21, 9710.	1.8	25
42	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Research and Care, 2020, 8, e001706.	1.2	31
43	Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice. Biomedicine and Pharmacotherapy, 2020, 132, 110953.	2.5	25
44	Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control. Proceedings of the Nutrition Society, 2020, 79, 514-530.	0.4	22
45	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews, 2020, 159, 34-53.	6.6	21
46	The gut hormone receptor GIPR links energy availability to the control of hematopoiesis. Molecular Metabolism, 2020, 39, 101008.	3.0	12
47	Human islets contain a subpopulation of glucagon-like peptide-1 secreting Î± cells that is increased in type 2 diabetes. Molecular Metabolism, 2020, 39, 101014.	3.0	44
48	Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinsonâ€™s disease. Expert Opinion on Investigational Drugs, 2020, 29, 595-602.	1.9	34
49	Polygonatum cyrtonema Hua Polysaccharide Promotes GLP-1 Secretion from Enteroendocrine L-Cells through Sweet Taste Receptor-Mediated cAMP Signaling. Journal of Agricultural and Food Chemistry, 2020, 68, 6864-6872.	2.4	37
50	Multiparameter Peptide Optimization toward Stable Triple Agonists for the Treatment of Diabetes and Obesity. Advanced Therapeutics, 2020, 3, 2000052.	1.6	4
51	GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis. Obesity Surgery, 2020, 30, 3561-3569.	1.1	7
52	Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms. Peptides, 2020, 131, 170342.	1.2	45
53	Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs. Pharmaceutical Research, 2020, 37, 120.	1.7	9
54	Zwitterionic Polymer Conjugated Glucagon-like Peptide-1 for Prolonged Glycemic Control. Bioconjugate Chemistry, 2020, 31, 1812-1819.	1.8	13
55	A Role for GLP-1 in Treating Hyperphagia and Obesity. Endocrinology, 2020, 161, .	1.4	52

#	Article	IF	Citations
56	Mof regulates glucose level via altering different Î±-cell subset mass and intra-islet glucagon-like peptide-1, glucagon secretion. Metabolism: Clinical and Experimental, 2020, 109, 154290.	1.5	6
57	Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice. Peptides, 2020, 131, 170349.	1.2	16
58	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs, 2020, 29, 333-348.	1.9	94
59	Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age. International Journal of Molecular Sciences, 2020, 21, 4479.	1.8	31
60	Labeling and Characterization of Human GLP-1-Secreting L-cells in Primary Ileal Organoid Culture. Cell Reports, 2020, 31, 107833.	2.9	42
61	Effects of prebiotic dietary fibers and probiotics on human health: With special focus on recent advancement in their encapsulated formulations. Trends in Food Science and Technology, 2020, 102, 178-192.	7.8	62
62	Selective stimulation of colonic L cells improves metabolic outcomes in mice. Diabetologia, 2020, 63, 1396-1407.	2.9	45
63	The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation. RSC Advances, 2020, 10, 10245-10253.	1.7	4
64	Allan-Herndon-Dudley-Syndrome: Considerations about the Brain Phenotype with Implications for Treatment Strategies. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 414-422.	0.6	9
66	Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. Frontiers in Pharmacology, 2020, 11, 432.	1.6	36
67	GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss. Cell Reports, 2020, 31, 107543.	2.9	53
68	Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Molecular Metabolism, 2020, 37, 100990.	3.0	39
69	Pheochromocytoma With Adrenergic Biochemical Phenotype Shows Decreased GLP-1 Secretion and Impaired Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1878-1887.	1.8	13
70	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, 2020, 9, 947.	1.0	85
71	Effect of the glucagonâ€like peptideâ€1 analogue liraglutide versus placebo treatment on circulating proglucagonâ€derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 489-498.	2.2	14
72	An â€˜Ayurveda-Biologyâ€™ platform for integrative diabetes management. Journal of Ethnopharmacology, 2021, 268, 113575.	2.0	15
73	Molecular physiology of bile acid signaling in health, disease, and aging. Physiological Reviews, 2021, 101, 683-731.	13.1	184
74	Use of DREADD Technology to Identify Novel Targets for Antidiabetic Drugs. Annual Review of Pharmacology and Toxicology, 2021, 61, 421-440.	4.2	26

#	Article	IF	Citations
75	Glucose Sensing Mediated by Portal Glucagon-Like Peptide 1 Receptor Is Markedly Impaired in Insulin-Resistant Obese Animals. Diabetes, 2021, 70, 99-110.	0.3	8
76	Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107797.	1.2	5
77	Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Healthâ€"Pathophysiology and Therapeutic Strategies. Gastroenterology, 2021, 160, 573-599.	0.6	169
78	Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. Bioorganic Chemistry, 2021, 106, 104492.	2.0	11
79	The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice. Microbial Pathogenesis, 2021, 150, 104645.	1.3	11
80	Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine Reviews, 2021, 42, 101-132.	8.9	115
81	Pharmacogenomics of GPCR genes in type 2 diabetes and obesity. Current Opinion in Endocrine and Metabolic Research, 2021, 16, 128-135.	0.6	2
82	Paracrine and autocrine control of insulin secretion in human islets: evidence and pending questions. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E78-E86.	1.8	27
83	Gutâ€"adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?. Obesity Reviews, 2021, 22, e13130.	3.1	7
84	Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients, 2021, 13, 351.	1.7	28
85	The Physiology and Pharmacology of Diabetic Gastropathy Management. , 2021, , .		1
86	Metabolic Messengers: glucagon-like peptide 1. Nature Metabolism, 2021, 3, 142-148.	5.1	73
88	An Overview of Hypoglycemic Biological Drugs. , 2021, , 33-55.		1
89	Pharmacologie de l'obÃ©sitÃ© : vers de nouvelles options. , 2021, , 663-672.		0
90	Post-Infarction Inflammatory Alterations. , 2021, , 109-159.		0
91	Antidiabetic Properties of Curcumin: Insights on New Mechanisms. Advances in Experimental Medicine and Biology, 2021, 1291, 151-164.	0.8	8
92	Bitter Melon Extract Yields Multiple Effects on Intestinal Epithelial Cells and Likely Contributes to Anti-diabetic Functions. International Journal of Medical Sciences, 2021, 18, 1848-1856.	1.1	7
93	Low carbohydrate diet while taking dapagliflozin: A case report and review of literature. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 361-363.	1.8	3

#	Article	IF	Citations
94	Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 902.	1.8	11
95	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. International Journal of Molecular Sciences, 2021, 22, 660.	1.8	15
96	Imaging Meets Cytometry: Analyzing Heterogeneous Functional Microscopic Data from Living Cell Populations. Journal of Imaging, 2021, 7, 9.	1.7	2
97	Effects of intragastric administration of L-tryptophan on the glycaemic response to a nutrient drink in men with type 2 diabetes â€" impacts on gastric emptying, glucoregulatory hormones and glucose absorption. Nutrition and Diabetes, 2021, 11, 3.	1.5	5
98	Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans. Endocrine Connections, 2021, 10, 205-213.	0.8	4
99	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. International Journal of Neuropsychopharmacology, 2021, 24, 464-476.	1.0	11
100	Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue. Hypertension, 2021, 77, 729-738.	1.3	20
101	A Non-Perturbative Molecular Grafting Strategy for Stable and Potent Therapeutic Peptide Ligands. ACS Central Science, 2021, 7, 454-466.	5.3	5
102	Evidence for Glucagon Secretion and Function Within the Human Gut. Endocrinology, 2021, 162, .	1.4	3
103	Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. Journal of Endocrinology, 2021, 248, 145-154.	1.2	2
104	Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity. Biomolecules, 2021, 11, 286.	1.8	20
105	Exendin-4, a glucagon-like peptide receptor agonist, facilitates osteoblast differentiation via connexin43. Endocrine, 2021, 72, 672-680.	1.1	1
106	Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell. Journal of the American Chemical Society, 2021, 143, 3416-3429.	6.6	39
107	Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?. Nutrients, 2021, 13, 762.	1.7	33
108	The metabolic impact of small intestinal nutrient sensing. Nature Communications, 2021, 12, 903.	5.8	70
109	Circadian clocks in the digestive system. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 239-251.	8.2	65
111	GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo. BMC Biology, 2021, 19, 40.	1.7	10
112	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinsonâ€™s Disease. ACS Pharmacology and Translational Science, 2021, 4, 858-869.	2.5	12

#	Article	IF	Citations
113	Evidence for the existence and potential roles of intra-islet glucagon-like peptide-1. Islets, 2021, 13, 32-50.	0.9	8
114	A Review on the Efficacy and Safety of Oral Semaglutide. Drugs in R and D, 2021, 21, 133-148.	1.1	9
115	Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women. Nutrients, 2021, 13, 865.	1.7	11
116	Comparative Effects of Intragastric and Intraduodenal Administration of Quinine on the Plasma Glucose Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory Hormones and Gastric Emptying. Journal of Nutrition, 2021, 151, 1453-1461.	1.3	11
117	Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications. Journal of Neurochemistry, 2021, 158, 603-620.	2.1	8
118	Protective or Harmful: The Dual Roles of Autophagy in Diabetic Retinopathy. Frontiers in Medicine, 2021, 8, 644121.	1.2	29
119	Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study. Journal of the American Heart Association, 2021, 10, e019323.	1.6	28
120	(â€“)-Epicatechin and Anthocyanins Modulate GLP-1 Metabolism: Evidence from C57BL/6J Mice and GLUTag Cells. Journal of Nutrition, 2021, 151, 1497-1506.	1.3	23
121	Detour Ahead: Incretin Hormone Signaling Alters Its Intracellular Path as Î²-Cell Failure Progresses During Diabetes. Frontiers in Endocrinology, 2021, 12, 665345.	1.5	4
122	Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug and Alcohol Dependence, 2021, 221, 108614.	1.6	16
123	Activation of PPG neurons following acute stressors differentially involves hindbrain serotonin in male rats. Neuropharmacology, 2021, 187, 108477.	2.0	7
124	Delivery of oligonucleotideâ€based therapeutics: challenges and opportunities. EMBO Molecular Medicine, 2021, 13, e13243.	3.3	181
125	Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy. Neuropharmacology, 2021, 187, 108498.	2.0	25
126	Insulin Signaling in Arthritis. Frontiers in Immunology, 2021, 12, 672519.	2.2	19
128	Effects of Bitter Substances on GI Function, Energy Intake and Glycaemia-Do Preclinical Findings Translate to Outcomes in Humans?. Nutrients, 2021, 13, 1317.	1.7	8
129	Emerging Role of Caveolin-1 in GLP-1 Action. Frontiers in Endocrinology, 2021, 12, 668012.	1.5	3
130	The isletâ€™s bridesmaid becomes the bride: Proglucagon-derived peptides deliver transformative therapies. Cell, 2021, 184, 1945-1948.	13.5	3
132	Glucagon's Metabolic Action in Health and Disease. , 2021, 11, 1759-1783.		21

#	Article	IF	Citations
133	A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia. Cellular and Molecular Neurobiology, 2022, 42, 1995-2002.	1.7	2
134	Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sciences, 2021, 270, 118966.	2.0	11
135	Obesity therapeutics: The end of the beginning. Cell Metabolism, 2021, 33, 705-706.	7.2	9
136	GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action. Frontiers in Endocrinology, 2021, 12, 652628.	1.5	3
137	Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats. Frontiers in Veterinary Science, 2021, 8, 661546.	0.9	0
138	Glucose Metabolism in Burnsâ€"What Happens?. International Journal of Molecular Sciences, 2021, 22, 5159.	1.8	7
139	The Function of Gastrointestinal Hormones in Obesityâ€"Implications for the Regulation of Energy Intake. Nutrients, 2021, 13, 1839.	1.7	24
140	Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic Research in Cardiology, 2021, 116, 32.	2.5	32
141	Protective properties of GLPâ€1 and associated peptide hormones in neurodegenerative disorders. British Journal of Pharmacology, 2022, 179, 695-714.	2.7	55
142	Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems. European Journal of Medicinal Chemistry, 2021, 217, 113372.	2.6	35
143	Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3778-e3780.	1.8	3
144	Whole-brain activation signatures of weight-lowering drugs. Molecular Metabolism, 2021, 47, 101171.	3.0	25
145	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion, 2021, 58, 72-82.	1.6	13
146	Isoprenoid Derivatives of Lysophosphatidylcholines Enhance Insulin and GLP-1 Secretion through Lipid-Binding GPCRs. International Journal of Molecular Sciences, 2021, 22, 5748.	1.8	7
147	What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?. Cell Reports Medicine, 2021, 2, 100284.	3.3	4
148	Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacological Reports, 2021, 73, 1020-1032.	1.5	23
149	The therapeutic potential of GLPâ€1 receptor biased agonism. British Journal of Pharmacology, 2022, 179, 492-510.	2.7	27
150	The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism. Cell Reports, 2021, 35, 109163.	2.9	50

#	Article	IF	Citations
151	Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus. Obesity Medicine, 2021, 23, 100329.	0.5	7
152	Gut-brain communication and obesity: understanding functions of the vagus nerve. Journal of Clinical Investigation, 2021, 131, .	3.9	43
153	Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review. Advances in Nutrition, 2021, 12, 2540-2552.	2.9	10
154	GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation, 2021, 131, .	3.9	78
155	Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes. Pharmaceuticals, 2021, 14, 586.	1.7	33
156	Gastrointestinal pathophysiology during endurance exercise: endocrine, microbiome, and nutritional influences. European Journal of Applied Physiology, 2021, 121, 2657-2674.	1.2	17
157	Glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. Transplant International, 2021, 34, 1341-1359.	0.8	9
158	New Aspects of Diabetes Research and Therapeutic Development. Pharmacological Reviews, 2021, 73, 1001-1015.	7.1	10
159	GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. Diabetes, 2021, 70, 1938-1944.	0.3	17
160	Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology, 2021, 17, 484-495.	4.3	224
161	Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective. Annual Review of Nutrition, 2021, 41, 177-202.	4.3	27
162	Mitochondrial protein IF1 is a potential regulator of glucagon-like peptide (GLP-1) secretion function of the mouse intestine. Acta Pharmaceutica Sinica B, 2021, 11, 1568-1577.	5.7	6
163	GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimerâ€™s disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway. Biochemical Pharmacology, 2021, 188, 114578.	2.0	26
164	miR-802 regulates Paneth cell function and enterocyte differentiation in the mouse small intestine. Nature Communications, 2021, 12, 3339.	5.8	16
165	Weightâ€reducing, lipidâ€lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in highâ€fatâ€fed mice. Diabetes, Obesity and Metabolism, 2021, 23, 2215-2225.	2.2	4
166	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 503-515.	13.9	668
167	Probiotic and resveratrol normalize GLP-1 levels and oxidative stress in the intestine of diabetic rats. Metabolism Open, 2021, 10, 100093.	1.4	21
168	Gastrointestinal Distension by Pectin-Containing Carbonated Solution Suppresses Food Intake and Enhances Glucose Tolerance via GLP-1 Secretion and Vagal Afferent Activation. Frontiers in Endocrinology, 2021, 12, 676869.	1.5	10

#	Article	IF	Citations
169	Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity. International Journal of Molecular Sciences, 2021, 22, 6623.	1.8	12
170	A 2021 Update on the Use of Liraglutide in the Modern Treatment of â€˜Diabesityâ€™: A Narrative Review. Medicina (Lithuania), 2021, 57, 669.	0.8	14
171	The Role of GIP in the Regulation of GLP-1 Satiety and Nausea. Diabetes, 2021, 70, 1956-1961.	0.3	22
172	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. Frontiers in Endocrinology, 2021, 12, 694284.	1.5	22
173	Mutational Landscape of the Proglucagon-Derived Peptides. Frontiers in Endocrinology, 2021, 12, 698511.	1.5	7
174	Effects of glucagonâ€like peptideâ€1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. Journal of Diabetes Investigation, 2021, 12, 2162-2171.	1.1	12
175	TCF7 is not essential for glucose homeostasis in mice. Molecular Metabolism, 2021, 48, 101213.	3.0	1
176	The Enigmatic N-Terminal Domain of Proglucagon; A Historical Perspective. Frontiers in Endocrinology, 2021, 12, 683089.	1.5	3
177	Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl3-induced Alzheimer-like pathology model. Scientific Reports, 2021, 11, 12040.	1.6	17
178	Identification of Multiple Pancreatic and Extra-Pancreatic Pathways Underlying the Glucose-Lowering Actions of Acacia arabica Bark in Type-2 Diabetes and Isolation of Active Phytoconstituents. Plants, 2021, 10, 1190.	1.6	8
179	The diverse effects of brain glucagonâ€like peptide 1 receptors on ingestive behaviour. British Journal of Pharmacology, 2022, 179, 571-583.	2.7	12
180	Glucose-induced insulin secretion in isolated human islets: Does it truly reflect Î²-cell function inÂvivo?. Molecular Metabolism, 2021, 48, 101212.	3.0	28
181	Effect of Medical and Surgical Interventions on Î±-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care, 2021, 44, 1948-1960.	4.3	2
182	Smart-watch-programmed green-light-operated percutaneous control of therapeutic transgenes. Nature Communications, 2021, 12, 3388.	5.8	29
183	Excess of glucocorticoids during late gestation impairs the recovery of offspringâ€™s Î²â€cell function after a postnatal injury. FASEB Journal, 2021, 35, e21828.	0.2	2
184	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. Expert Opinion on Pharmacotherapy, 2021, 22, 1-22.	0.9	2
185	Costus spp e sua relevÃ¢ncia medicinal: Uma revisÃ£o integrativa. Research, Society and Development, 2021, 10, e4410816902.	0.0	0
186	Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Molecular Metabolism, 2021, 49, 101181.	3.0	39

#	Article	IF	Citations
187	Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals. Frontiers in Endocrinology, 2021, 12, 700066.	1.5	6
188	Learning of food preferences: mechanisms and implications for obesity & metabolic diseases. International Journal of Obesity, 2021, 45, 2156-2168.	1.6	36
189	How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 2021, 10, R200-R212.	0.8	17
190	Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion. Endocrinology, 2021, 162, .	1.4	1
191	Glucagon-like peptide-1 attenuated carboxymethyl lysine induced neuronal apoptosis via peroxisome proliferation activated receptor-Î³. Aging, 2021, 13, 19013-19027.	1.4	6
192	GLP-2 Is Locally Produced From Human Islets and Balances Inflammation Through an Inter-Islet-Immune Cell Crosstalk. Frontiers in Endocrinology, 2021, 12, 697120.	1.5	10
193	Reappraising the role of the vagus nerve in GLPâ€1â€mediated regulation of eating. British Journal of Pharmacology, 2022, 179, 584-599.	2.7	25
194	Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. Biochemical Pharmacology, 2021, 190, 114656.	2.0	8
195	Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes and Endocrinology,the, 2021, 9, 525-544.	5.5	121
196	Brain GLPâ€1 and the regulation of food intake: GLPâ€1 action in the brain and its implications for GLPâ€1 receptor agonists in obesity treatment. British Journal of Pharmacology, 2022, 179, 557-570.	2.7	46
197	Mind affects matter: Hindbrain GLP1 neurons link stress, physiology and behaviour. Experimental Physiology, 2021, 106, 1853-1862.	0.9	7
198	Contribution of Mitochondria to Insulin Secretion by Various Secretagogues. Antioxidants and Redox Signaling, 2022, 36, 920-952.	2.5	10
199	GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nature Reviews Endocrinology, 2021, 17, 592-607.	4.3	162
200	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 29-38.	1.8	82
201	Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. Hepatology, 2021, 74, 2154-2169.	3.6	22
202	L-Cell Expression of Melanocortin-4-Receptor Is Marginal in Most of the Small Intestine in Mice and Humans and Direct Stimulation of Small Intestinal Melanocortin-4-Receptors in Mice and Rats Does Not Affect GLP-1 Secretion. Frontiers in Endocrinology, 2021, 12, 690387.	1.5	2
203	GIP Receptor Agonism Attenuates GLP-1 Receptor Agonistâ€"Induced Nausea and Emesis in Preclinical Models. Diabetes, 2021, 70, 2545-2553.	0.3	59
204	Slow digestionâ€oriented dietary strategy to sustain the secretion of GLPâ€1 for improved glucose homeostasis. Comprehensive Reviews in Food Science and Food Safety, 2021, 20, 5173-5196.	5.9	14

#	Article	IF	Citations
205	Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events. Cell Reports, 2021, 36, 109609.	2.9	3
206	Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia. Pharmacological Research, 2021, 170, 105693.	3.1	4
207	Exendin-4 stimulates autophagy in pancreatic Î²-cells via the RAPGEF/EPAC-Ca²⁺-PPP3/calcineurin-TFEB axis. Autophagy, 2022, 18, 799-815.	4.3	20
208	Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6Âj mice. Journal of Physiology and Biochemistry, 2021, , 1.	1.3	2
209	Future perspectives in diabesity treatment: Semaglutide, a glucagonâ€'like peptideÂ1 receptor agonist (Review). Experimental and Therapeutic Medicine, 2021, 22, 1167.	0.8	7
210	MECHANISMS IN ENDOCRINOLOGY: The gutâ€"brain axis: regulating energy balance independent of food intake. European Journal of Endocrinology, 2021, 185, R75-R91.	1.9	13
211	Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 1589-1602.	0.9	0
212	Glucagonâ€like peptideâ€1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. British Journal of Pharmacology, 2022, 179, 542-556.	2.7	19
213	Glucagonâ€like peptideâ€1 receptor agonist treatment of high carbohydrate intakeâ€induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca²⁺ abnormalities and mitochondrial dysfunction. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 46-59.	0.9	10
214	L-cell Arntl is required for rhythmic glucagon-like peptide-1 secretion and maintenance of intestinal homeostasis. Molecular Metabolism, 2021, 54, 101340.	3.0	12
215	IBI362Â(LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine, 2021, 39, 101088.	3.2	23
216	The enteroinsular axis during hospitalization in newborn foals. Domestic Animal Endocrinology, 2022, 78, 106686.	0.8	1
217	Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects. European Journal of Pharmacology, 2021, 907, 174203.	1.7	3
218	Unveiling the Metabolic Effects of Glycomacropeptide. International Journal of Molecular Sciences, 2021, 22, 9731.	1.8	1
219	Glucagonâ€like peptideâ€1 (GLPâ€1) signalling in the brain: From neural circuits and metabolism to therapeutics. British Journal of Pharmacology, 2022, 179, 600-624.	2.7	21
220	Redox Signaling is Essential for Insulin Secretion. , 0, , .		0
221	Non-glucose modulators of insulin secretion in healthy humans: (dis)similarities between islet and in vivo studies. Metabolism: Clinical and Experimental, 2021, 122, 154821.	1.5	5
222	A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. Peptides, 2021, 143, 170597.	1.2	8

#	Article	IF	Citations
223	Metabolic homeostasis: itâ€™s all in the timing. Endocrinology, 2022, 163, .	1.4	5
224	A Novel Identified Peptide Hormone â€œMetabolitinâ€•Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-9.	0.5	2
225	Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Reports Medicine, 2021, 2, 100387.	3.3	33
226	Homeostatic regulation of food intake. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101794.	0.7	19
227	Advances in GLP-1 treatment: focus on oral semaglutide. Diabetology and Metabolic Syndrome, 2021, 13, 99.	1.2	11
228	The physiological control of eating: signals, neurons, and networks. Physiological Reviews, 2022, 102, 689-813.	13.1	60
229	Longâ€term drench of exopolysaccharide from <scp>Leuconostoc pseudomesenteroides XG5</scp> protects against type 1 diabetes of <scp>NOD</scp> mice via stimulating <scp>GLP</scp>â€1 secretion. Journal of the Science of Food and Agriculture, 2022, 102, 2023-2031.	1.7	2
230	Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor. Biochemical and Biophysical Research Communications, 2021, 578, 84-90.	1.0	14
231	GsÎ±-dependent signaling is required for postnatal establishment of a functional Î²-cell mass. Molecular Metabolism, 2021, 53, 101264.	3.0	6
232	Chitosan for biomedical applications, promising antidiabetic drug delivery system, and new diabetes mellitus treatment based on stem cell. International Journal of Biological Macromolecules, 2021, 190, 417-432.	3.6	25
233	Novel Î²-mannanase/GLP-1 fusion peptide high effectively ameliorates obesity in a mouse model by modifying balance of gut microbiota. International Journal of Biological Macromolecules, 2021, 191, 753-763.	3.6	25
234	Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice. Peptides, 2021, 146, 170650.	1.2	1
235	Diabetes mellitus and Parkinsonâ€™s disease: dangerous liaisons between insulin and dopamine. Neural Regeneration Research, 2022, 17, 523.	1.6	21
236	GPCR's and Endocrinology. , 2021, , .		1
237	The Pancreatic Î²-Cell: The Perfect Redox System. Antioxidants, 2021, 10, 197.	2.2	16
238	GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. ACS Pharmacology and Translational Science, 2021, 4, 296-313.	2.5	24
239	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	3.9	102
240	G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduction and Targeted Therapy, 2021, 6, 7.	7.1	241

#	Article	IF	Citations
241	Paracrine signaling in islet function and survival. Journal of Molecular Medicine, 2020, 98, 451-467.	1.7	24
242	Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. Brain Structure and Function, 2021, 226, 225-245.	1.2	20
243	Central and peripheral GLP-1 systems independently suppress eating. Nature Metabolism, 2021, 3, 258-273.	5.1	107
244	Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by Âμ-opioid receptor stimulation of the nucleus accumbens in the rat. NeuroReport, 2020, 31, 1283-1288.	0.6	9
246	Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice. JCI Insight, 2020, 5, .	2.3	11
247	Gs/Gq signaling switch in Î² cells defines incretin effectiveness in diabetes. Journal of Clinical Investigation, 2020, 130, 6639-6655.	3.9	46
248	FGF21 and the Physiological Regulation of Macronutrient Preference. Endocrinology, 2020, 161, .	1.4	57
249	GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice. Endocrinology, 2020, 161, .	1.4	16
250	Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging, 2021, 13, 525-536.	1.4	12
251	Glucagonoma: From skin lesions to the neuroendocrine component (Review). Experimental and Therapeutic Medicine, 2020, 20, 3389-3393.	0.8	11
252	The Molecular Mechanisms of Hypoglycemic Properties and Safety Profiles of Swietenia Macrophylla Seeds Extract: A Review. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 370-388.	0.1	1
253	Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 735824.	1.5	41
254	Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Frontiers in Medicine, 2021, 8, 761538.	1.2	25
255	Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity inÂvivo. Molecular Metabolism, 2021, 54, 101352.	3.0	18
256	A comprehensive review of the neuroscience of ingestion: the physiological control of eating: signals, neurons, and networks. Physiological Reviews, 2022, 102, 319-322.	13.1	0
257	Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide. JCI Insight, 2021, 6, .	2.3	23
258	Effect of the Gintonin-Enriched Fraction on Glucagon-Like-Protein-1 Release. Molecules, 2021, 26, 6298.	1.7	1
259	Brain energy failure in dementia syndromes: Opportunities and challenges for glucagonâ€like peptideâ€1 receptor agonists. Alzheimer's and Dementia, 2022, 18, 478-497.	0.4	13

#	Article	IF	Citations
260	Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide. Meditsinskiy Sovet, 2020, , 50-55.	0.1	0
261	In vitro and in silico evaluation of multifunctional properties of bioactive synthetic peptides identified in milk fermented with Lactococcus lactis NRRL B-50571 and NRRL B-50572. LWT - Food Science and Technology, 2022, 154, 112581.	2.5	16
262	Elevated Glucagon-like Peptide-1 and a Th2 Shift May Support Reduced Prevalence of Thoracic Aortic Aneurysm in Patients with Diabetes. Journal of Cardiovascular Development and Disease, 2021, 8, 143.	0.8	1
263	Anosmia and dysgeusia among COVIDâ€19 patients are associated with low levels of serum Glucagonâ€like peptide 1 (GLPâ€1). International Journal of Clinical Practice, 2021, , e14996.	0.8	4
264	Hormonal Regulation of Oxidative Phosphorylation in the Brain in Health and Disease. Cells, 2021, 10, 2937.	1.8	9
265	Phytochemicals modulate pancreatic islet Î² cell function through glucagon-like peptide-1-related mechanisms. Biochemical Pharmacology, 2022, 197, 114817.	2.0	4
266	Overview of Type 2 Diabetes Drugs on the Market. Journal of Biosciences and Medicines, 2020, 08, 1-14.	0.1	2
267	Intestinal microflora in metabolic diseases. World Chinese Journal of Digestology, 2020, 28, 1192-1199.	0.0	1
268	The Gut Microbiome: Connecting Diet, Glucose Homeostasis, and Disease. Annual Review of Medicine, 2022, 73, 469-481.	5.0	20
270	Physicochemical, morpho-structural, and biological characterization of polysaccharides from three Polygonatum spp. RSC Advances, 2021, 11, 37952-37965.	1.7	14
271	Vasodilator Dysfunction in Human Obesity. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	1
272	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	2.2	17
273	Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Molecular Metabolism, 2022, 55, 101407.	3.0	24
274	<scp>Captureâ€Release</scp> Strategy Facilitates Rapid Enzymatic Assembly of Oligosaccharides. Chinese Journal of Chemistry, 2022, 40, 343-350.	2.6	5
275	Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Î²-Cell Regeneration In Situ in Type 1 Diabetic Mice. Journal of Diabetes Research, 2021, 2021, 1-10.	1.0	3
276	Protein Appetite at the Interface between Nutrient Sensing and Physiological Homeostasis. Nutrients, 2021, 13, 4103.	1.7	11
278	Complementary and antagonistic effects of combined glucagonâ€like peptideâ€2 and glucagonâ€like peptideâ€1 receptor agonist administration on parameters relevant to short bowel syndrome. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1361-1370.	1.3	4
279	Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Scientific Reports, 2021, 11, 22521.	1.6	27

#	Article	IF	Citations
280	The manifold roles of protein S-nitrosylation in the life of insulin. Nature Reviews Endocrinology, 2022, 18, 111-128.	4.3	10
281	Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes. Molecules, 2021, 26, 6907.	1.7	7
282	Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery, 2022, 21, 201-223.	21.5	357
283	Islet Biology During COVID-19: Progress and Perspectives. Canadian Journal of Diabetes, 2022, 46, 419-427.	0.4	2
284	Editorial: Proglucagon-Derived Peptides. Frontiers in Endocrinology, 2021, 12, 776871.	1.5	2
285	Pharmacology of NASH. , 2021, , .		0
286	Efficacy and safety of highâ€dose glucagonâ€like peptideâ€1, glucagonâ€like peptideâ€1/glucoseâ€dependent insulinotropic peptide, and glucagonâ€like peptideâ€1/glucagon receptor agonists in type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 788-805.	2.2	17
287	Characterization of endogenous peptides from Dromedary and Bactrian camel milk. European Food Research and Technology, 2022, 248, 1149-1160.	1.6	10
288	Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy â€“ A review. Peptides, 2022, 147, 170706.	1.2	7
289	GLP-1a: Going beyond Traditional Use. International Journal of Molecular Sciences, 2022, 23, 739.	1.8	31
290	Yacon-based product improves intestinal hypertrophy and modulates the production of glucagon-like peptide-1 in postmenopausal experimental model. Life Sciences, 2022, 291, 120245.	2.0	3
291	Classical and non-classical islet peptides in the control of Î²-cell function. Peptides, 2022, 150, 170715.	1.2	3
292	Metabolic hormones in human breast milk are preserved by high hydrostatic pressure processing but reduced by Holder pasteurization. Food Chemistry, 2022, 377, 131957.	4.2	9
293	Glycaemic Control in Diabetes. Handbook of Experimental Pharmacology, 2021, , 47-71.	0.9	1
294	(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. Lipids in Health and Disease, 2022, 21, 9.	1.2	17
295	The Metabolic Role and Therapeutic Potential of the Microbiome. Endocrine Reviews, 2022, 43, 907-926.	8.9	26
296	The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases. International Journal of Molecular Sciences, 2022, 23, 1600.	1.8	11
297	Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases. Frontiers in Pharmacology, 2021, 12, 805269.	1.6	6

#	Article	IF	Citations
298	Glucagonâ€like peptideâ€1: Are its roles as endogenous hormone and therapeutic wizard congruent?. Journal of Internal Medicine, 2022, 291, 557-573.	2.7	7
299	Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption. Drug Delivery, 2022, 29, 305-315.	2.5	9
300	Beneficial effects of blueberry supplementation on the components of metabolic syndrome: a systematic review and meta-analysis. Food and Function, 2022, , .	2.1	2
301	Association of fasting glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide with dyslipidemia in newly diagnosed diabetes. International Journal of Diabetes in Developing Countries, 0, , 1.	0.3	0
302	Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension. Medical Hypotheses, 2022, 158, 110739.	0.8	7
303	Identification and characterization of dipeptidyl peptidase IV inhibitory peptides from wheat gluten proteins. Journal of Cereal Science, 2022, 103, 103396.	1.8	10
304	Myricetin Increases Circulating Adropin Level after Activation of Glucagon-like Peptide 1 (GLP-1) Receptor in Type-1 Diabetic Rats. Pharmaceuticals, 2022, 15, 173.	1.7	6
305	The intestine and the microbiota in maternal glucose homeostasis during pregnancy. Journal of Endocrinology, 2022, 253, R1-R19.	1.2	11
306	Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metabolism, 2022, 34, 59-74.e10.	7.2	92
307	Gut HIF2Î± signaling is increased after VSG, and gut activation of HIF2Î± decreases weight, improves glucose, and increases GLP-1 secretion. Cell Reports, 2022, 38, 110270.	2.9	8
309	Acute effects of linagliptin on intact and total glucagonâ€like peptideâ€1 and gastric inhibitory polypeptide levels in insulinâ€dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, Obesity and Metabolism, 2022, 24, 806-815.	2.2	0
310	Gut Dysbiosis and Immune System in Atherosclerotic Cardiovascular Disease (ACVD). Microorganisms, 2022, 10, 108.	1.6	25
311	Metabolic Adaptions/Reprogramming in Islet Beta-Cells in Response to Physiological Stimulatorsâ€”What Are the Consequences. Antioxidants, 2022, 11, 108.	2.2	3
312	Nutrient sensing in the gut and the regulation of appetite. Current Opinion in Endocrine and Metabolic Research, 2022, 23, 100318.	0.6	1
313	GLP-1 and GIP receptor signaling in beta cells â€“ A review of receptor interactions and co-stimulation. Peptides, 2022, 151, 170749.	1.2	29
314	Salmonella Infection Causes Hyperglycemia for Decreased GLP-1 Content by Enteroendocrine L Cells Pyroptosis in Pigs. International Journal of Molecular Sciences, 2022, 23, 1272.	1.8	5
315	Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism: Clinical and Experimental, 2022, 129, 155157.	1.5	8
316	Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells. Life Sciences, 2022, 292, 120331.	2.0	4

#	Article	IF	Citations
317	The regulation of PKA signaling in obesity and in the maintenance of metabolic health. , 2022, 237, 108113.		35
318	Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus. Vitamins and Hormones, 2022, 118, 457-478.	0.7	7
319	Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Scientific Reports, 2022, 12, 2226.	1.6	16
320	Omarigliptin/galangin combination mitigates lipopolysaccharide-induced neuroinflammation in rats: Involvement of glucagon-like peptide-1, toll-like receptor-4, apoptosis and Akt/GSK-3Î² signaling. Life Sciences, 2022, 295, 120396.	2.0	10
321	Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology, 2022, 919, 174800.	1.7	7
322	Cardiovascular effects of GLP-1 receptor agonism. Advances in Pharmacology, 2022, , 213-254.	1.2	5
323	Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?. Journal of Orthopaedic Translation, 2022, 32, 121-129.	1.9	12
324	Research Progress of Slimming Products and Their Pharmacological Mechanisms. Hans Journal of Food and Nutrition Science, 2022, 11, 73-79.	0.0	0
325	Adipose tissue. , 2022, , 209-228.		0
326	Intestinal HIF-2Î± Regulates GLP-1 Secretion via Lipid Sensing in L-Cells. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1057-1072.	2.3	7
327	The Role of T Cells in Obesity-Associated Inflammation and Metabolic Disease. Immune Network, 2022, 22, e13.	1.6	16
328	Measures of glucose homeostasis during and after duodenal exclusion using a duodenal-jejunal bypass liner in a normoglycemic, nonobese canine model. Surgery for Obesity and Related Diseases, 2022, , .	1.0	1
329	Evidence and possible mechanisms of probiotics in the management of type 1 diabetes mellitus. Journal of Diabetes and Metabolic Disorders, 2022, 21, 1081-1094.	0.8	9
330	The Influence of Whey Protein Heating Parameters on Their Susceptibility to Digestive Enzymes and the Antidiabetic Activity of Hydrolysates. Foods, 2022, 11, 829.	1.9	2
331	The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Frontiers in Endocrinology, 2022, 13, 863184.	1.5	5
332	Enteroendocrine System and Gut Barrier in Metabolic Disorders. International Journal of Molecular Sciences, 2022, 23, 3732.	1.8	8
333	Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective. Gastroenterology, 2022, 162, 1858-1875.e2.	0.6	45
334	The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice. Biology, 2022, 11, 431.	1.3	7

#	Article	IF	Citations
335	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. Frontiers in Endocrinology, 2022, 13, 838410.	1.5	42
336	Possible Role of rs7903146 Polymorphism of the Transcription Factor 7-Like 2 Gene in Genetic Predisposition to Type 2 Diabetes. Pakistan Journal of Biological Sciences, 2022, 25, 218-225.	0.2	1
337	A guide to designing photocontrol in proteins: methods, strategies and applications. Biological Chemistry, 2022, 403, 573-613.	1.2	14
338	Receptor-associated independent cAMP nanodomains mediate spatiotemporal specificity of GPCR signaling. Cell, 2022, 185, 1130-1142.e11.	13.5	85
339	Current Management of Glycemia in Children with Type 1 Diabetes Mellitus. New England Journal of Medicine, 2022, 386, 1155-1164.	13.9	14
340	Structural and immunoendocrine remodeling in gut, pancreas and thymus in weaning rats fed powdered milk diets rich in Maillard reactants. Scientific Reports, 2022, 12, 4039.	1.6	1
341	Neurohormonal Changes in the Gutâ€“Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery. International Journal of Molecular Sciences, 2022, 23, 3339.	1.8	21
342	Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics. Scandinavian Journal of Gastroenterology, 2022, , 1-9.	0.6	3
343	Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research. Frontiers in Neurology, 2022, 13, 844697.	1.1	12
344	Abnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus. Medical Herald of the South of Russia, 2022, 13, 24-42.	0.2	2
345	Binge eating disorder. Nature Reviews Disease Primers, 2022, 8, 16.	18.1	67
347	GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation. Cells, 2022, 11, 1187.	1.8	9
348	Effect of Prosopis ruscifolia on incretin and insulin secretion in alloxan-induced hyperglycemic rats. Vitae, 2022, 29, .	0.2	0
349	Incretin-induced changes in the transcriptome of skeletal muscles of fa/fa Zucker rat (ZFR) with obesity, without diabetes. International Journal of Obesity, 2022, , .	1.6	0
350	Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents. European Journal of Medicinal Chemistry, 2022, 233, 114214.	2.6	7
351	Effect of dual inhibition of DPP4 and SGLT2 on tacrolimus-induced diabetes mellitus and nephrotoxicity in a rat model. American Journal of Transplantation, 2022, 22, 1537-1549.	2.6	8
352	Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals. Veterinary and Animal Science, 2022, 16, 100245.	0.6	4
353	Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies. Neuroscience and Biobehavioral Reviews, 2022, 137, 104642.	2.9	27

#	Article	IF	Citations
354	GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacologica Sinica, 2022, 43, 1156-1166.	2.8	11
355	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovascular Diabetology, 2021, 20, 237.	2.7	14
356	Beta cell function, incretin hormones, and incretin effect in obese children and adolescents with prediabetes. Pediatric Diabetes, 2022, 23, 203-211.	1.2	2
357	Physiological Role of Bile Acids Modified by the Gut Microbiome. Microorganisms, 2022, 10, 68.	1.6	35
358	Modulation of Prostanoids Profile and Counter-Regulation of SDF-1Î±/CXCR4 and VIP/VPAC2 Expression by Sitagliptin in Non-Diabetic Rat Model of Hepatic Ischemia-Reperfusion Injury. International Journal of Molecular Sciences, 2021, 22, 13155.	1.8	1
359	Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons. Frontiers in Behavioral Neuroscience, 2021, 15, 724030.	1.0	6
360	Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice. Frontiers in Pharmacology, 2021, 12, 781856.	1.6	6
361	Colonic Delivery of Î±â€Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagonâ€Like Peptideâ€1 Secretion and Inhibits Food Intake in Mice. Molecular Nutrition and Food Research, 2022, 66, e2100978.	1.5	4
362	GLP-1 Suppresses Feeding Behaviors and Modulates Neuronal Electrophysiological Properties in Multiple Brain Regions. Frontiers in Molecular Neuroscience, 2021, 14, 793004.	1.4	12
363	The Enteroendocrine System in Obesity. Handbook of Experimental Pharmacology, 2022, , 109-129.	0.9	6
364	Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus. Biotechnology Letters, 2022, 44, 643-669.	1.1	6
365	The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 2022, 23, 4334.	1.8	30
366	Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid. International Journal of Molecular Sciences, 2022, 23, 4163.	1.8	4
367	Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists. ACS Chemical Biology, 2022, 17, 1249-1258.	1.6	2
368	Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal. Molecules, 2022, 27, 2478.	1.7	8
369	The multifaceted role of ATF4 in regulating glucose-stimulated insulin secretion. Biochemical and Biophysical Research Communications, 2022, 611, 165-171.	1.0	1
370	Physicochemical characterization and hypoglycemic potential of a novel polysaccharide from Polygonatum sibiricum Red through PI3K/Akt mediated signaling pathway. Journal of Functional Foods, 2022, 93, 105080.	1.6	7
373	HORDB a comprehensive database of peptide hormones. Scientific Data, 2022, 9, 187.	2.4	5

#	Article	IF	Citations
374	Dietary fiber in the prevention of obesity and obesity-related chronic diseases: From epidemiological evidence to potential molecular mechanisms. Critical Reviews in Food Science and Nutrition, 2023, 63, 8752-8767.	5.4	43
375	Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2022, 20, 321-328.	0.5	2
376	Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2154-2166.	1.8	10
377	What do I need to know about liraglutide (Saxenda), the glucagon-like peptide 1 receptor agonist for weight management in children with obesity?. Paediatrics and Child Health, 2022, 27, 201-202.	0.3	1
378	Liver Steatosis: A Marker of Metabolic Risk in Children. International Journal of Molecular Sciences, 2022, 23, 4822.	1.8	6
379	A GLPâ€1/glucagon (GCG)/CCK₂ receptors triâ€agonist provides new therapy for obesity and diabetes. British Journal of Pharmacology, 2022, 179, 4360-4377.	2.7	11
380	Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?. Frontiers in Endocrinology, 2022, 13, 868037.	1.5	11
381	Role of the gutâ€"brain axis in energy and glucose metabolism. Experimental and Molecular Medicine, 2022, 54, 377-392.	3.2	72
382	The Potential Role of Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum and Drymaria diandra, and Peptides Derived from Heterophyllin B as Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: An In Silico Study. Metabolites, 2022, 12, 387.	1.3	2
383	Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. European Journal of Endocrinology, 2022, 187, 75-84.	1.9	2
384	Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	4
385	Potensi Hibiscus sabdariffa Linn. Memodulasi GLP-1 dan Neuropeptide Y (NPY) di Nucleus Arcuatus pada Tikus Obes. Jurnal Kedokteran Meditek, 2022, 28, 159-168.	0.1	0
386	Interorgan communication through peripherally derived peptide hormones in Drosophila. Fly, 2022, 16, 152-176.	0.9	15
387	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends in Endocrinology and Metabolism, 2022, 33, 424-442.	3.1	23
388	Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment. Pharmacological Research, 2022, 180, 106237.	3.1	3
389	Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities. Neuropeptides, 2022, 94, 102250.	0.9	15
390	Regulation of body weight: Lessons learned from bariatric surgery. Molecular Metabolism, 2023, 68, 101517.	3.0	17
391	Sleeve Gastrectomy Improves High-Fat Dietâ€"Associated Hepatic Steatosis Independent of the Glucagon-like-Petpide-1 Receptor in Rats. Journal of Gastrointestinal Surgery, 2022, 26, 1607-1618.	0.9	0

#	Article	IF	Citations
393	Discovery of the GI Effects of GLP-1: An Historical Perspective. Digestive Diseases and Sciences, 2022, 67, 2716-2720.	1.1	5
394	Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence. Frontiers in Pharmacology, 0, 13, .	1.6	9
397	Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-17â€“36 Amide and Glucose-Dependent Insulinotropic Polypeptide. Toxins, 2022, 14, 389.	1.5	1
398	An inter-organ neural circuit for appetite suppression. Cell, 2022, 185, 2478-2494.e28.	13.5	53
399	The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders. Frontiers in Pharmacology, 0, 13, .	1.6	5
400	Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys. European Journal of Pharmaceutical Sciences, 2022, 175, 106218.	1.9	1
401	GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119300.	1.9	12
402	Central and peripheral regulations mediated by short-chain fatty acids on energy homeostasis. Translational Research, 2022, 248, 128-150.	2.2	22
403	Dimeric styrylpyrones with stimulating GLP-1 secretion activities from Alpinia kwangsiensis. Tetrahedron, 2022, 120, 132901.	1.0	1
404	Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury. Pharmaceuticals, 2022, 15, 720.	1.7	2
405	Gut microbiota, bile acids, and nature compounds. Phytotherapy Research, 2022, 36, 3102-3119.	2.8	7
406	Novel roles of mTORC2 in regulation of insulin secretion by actin filament remodeling. American Journal of Physiology - Endocrinology and Metabolism, 2022, 323, E133-E144.	1.8	3
407	GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells, 2022, 11, 2023.	1.8	11
408	Exercise Improves Spatial Learning and Memory Performance through the Central GLP-1 Receptors. Behavioural Neurology, 2022, 2022, 1-6.	1.1	0
409	In vivo and in vitro characterization of <scp>GL0034</scp>, a novel longâ€acting <scp>glucagonâ€like peptide</scp>â€1 receptor agonist. Diabetes, Obesity and Metabolism, 2022, 24, 2090-2101.	2.2	4
410	Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study. Biomolecules, 2022, 12, 877.	1.8	2
411	Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study. Metabolites, 2022, 12, 549.	1.3	1
412	Phloretin suppresses carbohydrate-induced GLP-1 secretion via inhibiting short chain fatty acid release from gut microbiome. Biochemical and Biophysical Research Communications, 2022, 621, 176-182.	1.0	3

#	Article	IF	Citations
413	Novel luciferaseâ€based GLPâ€1 reporter assay reveals naturallyâ€occurring secretagogues. British Journal of Pharmacology, 0, , .	2.7	1
414	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211080.	1.1	10
415	Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?. , 2022, 18, 35.		5
416	The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugsâ€”Therapeutic potential exploration in lung injury. Acta Pharmaceutica Sinica B, 2022, 12, 4040-4055.	5.7	10
417	Postprandial Dynamics of Proglucagon Cleavage Products and Their Relation to Metabolic Health. Frontiers in Endocrinology, 0, 13, .	1.5	0
418	Obesity, Weight Gain, and Fluid Overload in Peritoneal Dialysis. , 0, 2, .		3
419	Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism. Science Advances, 2022, 8, .	4.7	21
420	Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus. World Journal of Methodology, 2022, 12, 246-257.	1.1	6
421	Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules, 2022, 27, 4315.	1.7	56
422	Paracrine actions of GLP1 in the gut unraveled. , 0, , .		0
423	Firmicutes, Bacteroidetes and Actinobacteria in Human Milk and Maternal Adiposity. Nutrients, 2022, 14, 2887.	1.7	9
424	Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity. Clinical Nutrition, 2022, 41, 1969-1976.	2.3	6
425	The glucagonâ€like peptideâ€1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a postâ€mortem brain study. Addiction Biology, 2022, 27, .	1.4	7
426	Glial cells as integrators of peripheral and central signals in the regulation of energy homeostasis. Nature Metabolism, 2022, 4, 813-825.	5.1	19
427	Disrupted and Elevated Circadian Secretion of Glucagon-Like Peptide-1 in a Murine Model of Type 2 Diabetes. Endocrinology, 2022, 163, .	1.4	7
428	Post-transplant diabetes mellitus following heart transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1537-1546.	0.3	6
430	In Vivo and In Vitro Comparison of the DPP-IV Inhibitory Potential of Food Proteins from Different Origins after Gastrointestinal Digestion. International Journal of Molecular Sciences, 2022, 23, 8365.	1.8	4
431	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Reviews, 2023, 44, 14-32.	8.9	32

#	Article	IF	Citations
432	Hibiscus sabdariffa in Diabetes Prevention and Treatmentâ€"Does It Work? An Evidence-Based Review. Foods, 2022, 11, 2134.	1.9	9
433	Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 9583.	1.8	11
434	Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor. Cells, 2022, 11, 2587.	1.8	5
435	Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology. Biomedicines, 2022, 10, 2026.	1.4	16
436	Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. Frontiers in Nutrition, 0, 9, .	1.6	7
437	Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants. Expert Opinion on Investigational Drugs, 2022, 31, 957-964.	1.9	1
438	Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives. European Journal of Medicinal Chemistry, 2022, 243, 114668.	2.6	4
439	Efeitos adversos da semaglutida comparada Ã liraglutida: uma revisÃ£o integrativa de literatura. Research, Society and Development, 2022, 11, e579111033181.	0.0	0
440	Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes, Obesity and Metabolism, 2023, 25, 56-67.	2.2	7
441	Colonic Delivery of Nutrients for Sustained and Prolonged Release of Gut Peptides: A Novel Strategy for Appetite Management. Molecular Nutrition and Food Research, 2022, 66, .	1.5	2
442	The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic Î² cells. Cell Reports, 2022, 40, 111170.	2.9	7
443	Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics. Pharmacological Research, 2022, 184, 106411.	3.1	13
444	Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles. Journal of Medicinal Chemistry, 2022, 65, 11759-11775.	2.9	2
445	The neuropeptide landscape of human prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	26
446	Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and TÂcell-induced inflammation. Cell Metabolism, 2022, 34, 1514-1531.e7.	7.2	19
448	DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Military Medical Research, 2022, 9, .	1.9	4
449	Î²-cell dynamics in type 2 diabetes and in dietary and exercise interventions. Journal of Molecular Cell Biology, 2022, 14, .	1.5	10
450	Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review. Clinical Pharmacology: Advances and Applications, 0, Volume 14, 61-67.	0.8	3

#	Article	IF	Citations
451	Drug-Associated Parosmia: New Perspectives from the WHO Safety Database. Journal of Clinical Medicine, 2022, 11, 4641.	1.0	2
452	Secretion and Impact of Gut Hormones in Obesity and Diabetes. , 2022, , .		0
453	Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14.	0.0	0
454	Himalayan medicinal plants for treatment of diabetes: Their active components and underlying mechanism. Studies in Natural Products Chemistry, 2022, , 119-160.	0.8	0
455	Bioactive peptides: Improving the future of diabetes therapy. Studies in Natural Products Chemistry, 2022, , 41-74.	0.8	1
456	Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin. Endocrine Journal, 2023, 70, 149-159.	0.7	1
457	Life and Death of Pancreatic Î²-cells. , 2022, , .		0
458	Effects of long-term administration of theasinensin A on healthy C57BL/6J mice: Enhancing the function of epididymal white adipose tissue and regulating the colonic microenvironment. Food Chemistry, 2023, 403, 134477.	4.2	3
459	The Cytoskeletal Transport Protein, Secretagogin, Is Essential for Diurnal Glucagon-like Peptide-1 Secretion in Mice. Endocrinology, 2022, 163, .	1.4	3
460	Impact of biliopancreatic diversion with duodenal switch on glucose homeostasis and gut hormones and their correlations with appetite. Surgery for Obesity and Related Diseases, 2022, 18, 1392-1398.	1.0	3
461	Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	72
462	GLP-1 analogs in the treatment of obesity. Journal of Education, Health and Sport, 2022, 12, 334-342.	0.0	0
463	Short-Clustered Maltodextrin Activates Ileal Glucose-Sensing and Induces Glucagon-like Peptide 1 Secretion to Ameliorate Glucose Homeostasis in Type 2 Diabetic Mice. Journal of Agricultural and Food Chemistry, 2022, 70, 12604-12619.	2.4	3
464	Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 653-665.	4.3	2
465	Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history. Lancet Diabetes and Endocrinology,the, 2022, 10, 882-889.	5.5	6
466	Pathological and Therapeutic Advances in Parkinsonâ€™s Disease: Mitochondria in the Interplay. Journal of Alzheimer's Disease, 2023, 94, S399-S428.	1.2	15
467	The potential of glucagon-like peptide-1 receptor agonists in heart failure. Frontiers in Physiology, 0, 13, .	1.3	3
468	Systematic evaluation of antimicrobial food preservatives on glucose metabolism and gut microbiota in healthy mice. Npj Science of Food, 2022, 6, .	2.5	10

#	Article	IF	Citations
469	The Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell. Endocrinology, 2022, 163, .	1.4	3
470	Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. Nutrients, 2022, 14, 3775.	1.7	2
472	Glucagonâ€like peptideâ€1 receptor differentially controls mossy cell activity across the dentate gyrus longitudinal axis. Hippocampus, 2022, 32, 797-807.	0.9	3
473	Gut and obesity/metabolic disease: Focus on microbiota metabolites. MedComm, 2022, 3, .	3.1	15
475	Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the <scp>FIGHT</scp> trial. Diabetes, Obesity and Metabolism, 2023, 25, 189-197.	2.2	14
476	Herbal tea, a novel adjuvant therapy for treating type 2 diabetes mellitus: A review. Frontiers in Pharmacology, 0, 13, .	1.6	0
477	Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats. International Journal of Pharmaceutics, 2022, 628, 122255.	2.6	4
478	Liraglutide attenuates intestinal ischemia/reperfusion injury via NF-ÎºB and PI3K/Akt pathways in mice. Life Sciences, 2022, 309, 121045.	2.0	8
479	Consumption of barley flour increases gut fermentation and improves glucose intolerance via the short-chain fatty acid receptor GPR43 in obese male mice. Food and Function, 2022, 13, 10970-10980.	2.1	5
481	Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?. Journal of Clinical Medicine, 2022, 11, 6183.	1.0	4
482	How Arrestins and GRKs Regulate the Function of Long Chain Fatty Acid Receptors. International Journal of Molecular Sciences, 2022, 23, 12237.	1.8	1
483	Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus. Medicine (United States), 2022, 101, e31334.	0.4	5
484	Endosomal trafficking in metabolic homeostasis and diseases. Nature Reviews Endocrinology, 2023, 19, 28-45.	4.3	6
485	Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake. Cell and Bioscience, 2022, 12, .	2.1	12
486	Cheminformatics Identification and Validation of Dipeptidyl Peptidase-IV Modulators from Shikimate Pathway-Derived Phenolic Acids towards Interventive Type-2 Diabetes Therapy. Metabolites, 2022, 12, 937.	1.3	8
487	Alterations in mouse visceral adipose tissue <scp>mRNA</scp> expression of islet Gâ€proteinâ€coupled receptor ligands in obesity. Diabetic Medicine, 0, , .	1.2	2
488	Incretin and insulin signaling as novel therapeutic targets for Alzheimerâ€™s and Parkinsonâ€™s disease. Molecular Psychiatry, 2023, 28, 217-229.	4.1	21
490	Postprandial Glucose and Gastrointestinal Hormone Responses of Healthy Subjects to Wheat Biscuits Enriched with L-Arginine or Branched-Chain Amino Acids of Plant Origin. Nutrients, 2022, 14, 4381.	1.7	1

#	Article	IF	Citations
491	A Review of the Effects of Adolescent Cannabis Use on Physical Health. Child and Adolescent Psychiatric Clinics of North America, 2023, 32, 85-105.	1.0	2
492	An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism. Drug Design, Development and Therapy, 0, Volume 16, 3723-3735.	2.0	9
493	Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia. Nature Reviews Endocrinology, 2023, 19, 164-176.	4.3	18
494	Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet. Cureus, 2022, , .	0.2	0
495	Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines, 2022, 10, 2652.	1.4	3
496	Adipokines, Metabolic Hormones and Their Associations with Abdominal Obesity against a Background of Hyper-LDL-C in Young People. Journal of Personalized Medicine, 2022, 12, 1823.	1.1	0
497	Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ, The, 0, , e071380.	3.0	23
498	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology, 2022, 163, 1198-1225.	0.6	39
499	Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease. Frontiers in Pharmacology, 0, 13, .	1.6	4
500	Macronutrient intake: Hormonal controls, pathological states, and methodological considerations. Appetite, 2023, 180, 106365.	1.8	1
501	Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes. Cell Reports Medicine, 2022, 3, 100813.	3.3	6
502	The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimerâ€™s disease. Frontiers in Endocrinology, 0, 13, .	1.5	7
503	Polymorphism in ovine ADCY8 gene and its association with residual feed intake in Hu sheep. Animal Biotechnology, 0, , 1-8.	0.7	3
504	A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity. Frontiers in Endocrinology, 0, 13, .	1.5	12
506	Roseburia intestinalis Modulates PYY Expression in a New a Multicellular Model including Enteroendocrine Cells. Microorganisms, 2022, 10, 2263.	1.6	2
508	First-in-class oral semaglutide: Overcoming barriers of incretinisation in the Indian context. Indian Journal of Endocrinology and Metabolism, 2022, 26, 417.	0.2	0
509	Enteroendocrine peptides, growth, and the microbiome during the porcine weaning transition. Animal Microbiome, 2022, 4, .	1.5	3
510	The PPARÎ± Regulation of the Gut Physiology in Regard to Interaction with Microbiota, Intestinal Immunity, Metabolism, and Permeability. International Journal of Molecular Sciences, 2022, 23, 14156.	1.8	3

#	Article	IF	Citations
511	Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	1
512	Obesity pharmacotherapy: incretin action in the central nervous system. Trends in Pharmacological Sciences, 2023, 44, 50-63.	4.0	10
513	Four sidenotes about glucagon peptides. Peptides, 2023, 159, 170924.	1.2	0
514	Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. European Journal of Pharmacology, 2023, 938, 175439.	1.7	12
515	Predicting the response to GLP-1 receptor agonists: an unexpected role for Î²-arrestin-1. Lancet Diabetes and Endocrinology,the, 2023, 11, 3-4.	5.5	0
516	Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats. Brain Research Bulletin, 2023, 192, 142-155.	1.4	1
517	Harnessing gut cells for functional insulin production: Strategies and challenges. Biotechnology Notes, 2023, 4, 7-13.	0.7	0
518	Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease. European Journal of Pharmacology, 2023, 939, 175426.	1.7	0
519	PDX-1: A Promising Therapeutic Target to Reverse Diabetes. Biomolecules, 2022, 12, 1785.	1.8	13
520	Glucagon-like Peptide-1 Receptor in the Human Hypothalamus Is Associated with Body Mass Index and Colocalizes with the Anorexigenic Neuropeptide Nucleobindin-2/Nesfatin-1. International Journal of Molecular Sciences, 2022, 23, 14899.	1.8	3
521	Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. Cell Reports, 2022, 41, 111698.	2.9	8
522	The elusive cephalic phase insulin response: triggers, mechanisms, and functions. Physiological Reviews, 2023, 103, 1423-1485.	13.1	6
523	Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts. Journal of Physiology and Biochemistry, 2023, 79, 297-311.	1.3	4
524	Glucocorticoids, stress and eating: The mediating role of appetiteâ€regulating hormones. Obesity Reviews, 2023, 24, .	3.1	14
525	Glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1 secretion in humans: Characteristics and regulation. Journal of Diabetes Investigation, 2023, 14, 354-361.	1.1	4
526	Multidisciplinary Advances Address the Challenges in Developing Drugs against Transient Receptor Potential Channels to Treat Metabolic Disorders. ChemMedChem, 2023, 18, .	1.6	2
527	Voglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice. International Journal of Molecular Sciences, 2022, 23, 15938.	1.8	1
528	Circadian secretion rhythm of GLP-1 and its influencing factors. Frontiers in Endocrinology, 0, 13, .	1.5	5

#	Article	IF	Citations
529	Elevated Glucagon-like Peptide-1 Receptor Level in the Paraventricular Hypothalamic Nucleus of Type 2 Diabetes Mellitus Patients. International Journal of Molecular Sciences, 2022, 23, 15945.	1.8	0
530	Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 3961-3987.	1.1	5
531	Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19. Open Medicinal Chemistry Journal, 2022, 16, .	0.9	2
532	GLP-1R Signaling and Functional Molecules in Incretin Therapy. Molecules, 2023, 28, 751.	1.7	7
533	Exploring the Effects of Metabolism-Disrupting Chemicals on Pancreatic Î±-Cell Viability, Gene Expression and Function: A Screening Testing Approach. International Journal of Molecular Sciences, 2023, 24, 1044.	1.8	3
534	The predicted mechanisms and evidence of probiotics on type 2 diabetes mellitus (T2DM). Archives of Physiology and Biochemistry, 0, , 1-16.	1.0	5
535	Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research, 2023, 16, .	1.3	41
536	Galactooligosaccharides: Synthesis, metabolism, bioactivities and food applications. Critical Reviews in Food Science and Nutrition, 0, , 1-17.	5.4	2
537	Effects of GLP-1 on ovarian dysfunction in polycystic ovary syndrome: A protocol for systematic review and meta-analysis. Medicine (United States), 2023, 102, e32312.	0.4	1
538	VPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in rat pancreatic Î² cells. Experimental Cell Research, 2023, 423, 113471.	1.2	3
539	Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3Î² pathway. International Immunopharmacology, 2023, 115, 109647.	1.7	5
540	Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists. Peptides, 2023, 161, 170948.	1.2	2
541	Glucagon-like peptide-1 receptor regulates receptor of advanced glycation end products in high glucose-treated rat mesangial cells. Journal of the Chinese Medical Association, 2023, 86, 39-46.	0.6	0
542	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Design, Development and Therapy, 0, Volume 16, 4449-4461.	2.0	8
543	New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review of Medicine, 2023, 74, 125-139.	5.0	20
544	Interaction between inorganic phosphate concentration and glucose metabolism in mild refeeding syndrome model. Journal of Clinical Biochemistry and Nutrition, 2023, , .	0.6	0
545	Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. PLoS ONE, 2023, 18, e0278685.	1.1	9
546	The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Healthâ€"A Narrative Review. International Journal of Environmental Research and Public Health, 2023, 20, 2122.	1.2	2

#	Article	IF	Citations
547	Adverse Events Related to Tirzepatide. Journal of the Endocrine Society, 2023, 7, .	0.1	13
548	A Review of Fibraurea tinctoria and Its Component, Berberine, as an Antidiabetic and Antioxidant. Molecules, 2023, 28, 1294.	1.7	11
549	Current and emerging medications for the management of obesity in adults. Medical Journal of Australia, 2023, 218, 276-283.	0.8	5
550	Glucagonâ€like peptideâ€1 receptor agonists to expand the healthy lifespan: Current and future potentials. Aging Cell, 2023, 22, .	3.0	1
551	The activation of gastric inhibitory peptide/gastric inhibitory peptide receptor axis via sonic hedgehog signaling promotes the bridging of gapped nerves in sciatic nerve injury. Journal of Neurochemistry, 0, , .	2.1	0
552	Gut microbiota and oleoylethanolamide in the regulation of intestinal homeostasis. Frontiers in Endocrinology, 0, 14, .	1.5	3
553	Exercise and inactivity as modifiers of Î² cell function and type 2 diabetes risk. Journal of Applied Physiology, 2023, 134, 823-839.	1.2	0
554	Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy. Peptides, 2023, 163, 170978.	1.2	0
555	Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice. Atherosclerosis, 2023, 372, 19-31.	0.4	2
556	Activation of glucagon-like peptide-1 receptor in microglia exerts protective effects against sepsis-induced encephalopathy via attenuating endoplasmic reticulum stress-associated inflammation and apoptosis in a mouse model of sepsis. Experimental Neurology, 2023, 363, 114348.	2.0	4
557	Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL/6 mice: Implications on GLP-1R and cAMP/PKA signaling pathway in the hippocampus. Life Sciences, 2023, 320, 121546.	2.0	3
558	Evaluation of acute oral toxicity, anti-diabetic and antioxidant effects of Aloe vera flowers extract. Journal of Ethnopharmacology, 2023, 309, 116310.	2.0	4
559	Medicinal chemistry of non-peptidomimetic dipeptidyl peptidase IV (DPP IV) inhibitors for treatment of Type-2 diabetes mellitus: Insights on recent development. Journal of Molecular Structure, 2023, 1284, 135249.	1.8	4
560	Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine, 2022, 134, 5-17.	0.9	12
561	Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgraduate Medicine, 2022, 134, 1-4.	0.9	1
562	Short-term flaxseed oil, rich in omega 3, protects mice against metabolic damage caused by high-fat diet, but not inflammation. Journal of Nutritional Biochemistry, 2023, 114, 109270.	1.9	1
563	Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, openâ€label, parallelâ€group comparison study (<scp>SWITCHâ€SEMA</scp> 1 study). Diabetes, Obesity and Metabolism, 2023, 25, 1503-1511.	2.2	6
564	Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection. Matrix Biology, 2023, 116, 49-66.	1.5	2

#	Article	IF	Citations
565	Cellular and Molecular Mechanisms Associating Obesity to Bone Loss. Cells, 2023, 12, 521.	1.8	6
566	The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metabolism, 2023, 35, 253-273.	7.2	16
567	Hormonal Gutâ€"Brain Signaling for the Treatment of Obesity. International Journal of Molecular Sciences, 2023, 24, 3384.	1.8	8
568	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of Obesity and Metabolic Syndrome, 2023, 32, 25-45.	1.5	14
569	Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology and Metabolic Syndrome, 2023, 15, .	1.2	10
570	The Lipids and Volume in Satiation and Satiety (LIVES) Hypothesis: A Proposed Alternative Model for the Pathogenesis of Obesity. International Journal of Diabetology, 2023, 4, 64-75.	0.9	1
571	Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study. Journal of Biological Research (Italy), 0, , .	0.0	0
572	Metabolism-based approaches for autosomal dominant polycystic kidney disease. Frontiers in Molecular Biosciences, 0, 10, .	1.6	2
573	Impact of Oats on Appetite Hormones and Body Weight Management: A Review. Current Nutrition Reports, 2023, 12, 66-82.	2.1	5
574	GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers. Diabetes Therapy, 2023, 14, 777-786.	1.2	0
575	Famsin, a novel gut-secreted hormone, contributes to metabolic adaptations to fasting via binding to its receptor OLFR796. Cell Research, 2023, 33, 273-287.	5.7	1
576	Positive Health Outcomes Associated with Live Microbe Intake from Foods, Including Fermented Foods, Assessed using the NHANES Database. Journal of Nutrition, 2023, 153, 1143-1149.	1.3	18
577	Glucagon Acting at the GLP-1 Receptor Contributes to Î²-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice. Diabetes, 2023, 72, 599-610.	0.3	4
578	Neuroprotective Properties of Peptides. , 0, , .		1
579	Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity. Journal of Education, Health and Sport, 2023, 13, 196-205.	0.0	0
580	Targeting Glomerular Hemodynamics for Kidney Protection. , 2023, 30, 71-84.		2
581	Biological functions of CRTC2 and its role in metabolism-related diseases. Journal of Cell Communication and Signaling, 2023, 17, 495-506.	1.8	0
582	Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?. Stroke, 2023, 54, 1441-1451.	1.0	2

#	Article	IF	Citations
583	The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 575-595.	1.1	12
584	Is human obesity an inflammatory disease of the hypothalamus?. European Journal of Endocrinology, 2023, 188, R37-R45.	1.9	7
585	Fenugreek (Trigonella foenum-graecum L.) modulates energy metabolism and anti-inflammatory response in obesity via combinatorial analysis. Natural Products Journal, 2023, 13, .	0.1	0
587	Shortâ€term semaglutide treatment improves <scp>FGF21</scp> responsiveness in primary hepatocytes isolated from high fat diet challenged mice. Physiological Reports, 2023, 11, .	0.7	4
588	Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease. Journal of Controlled Release, 2023, 356, 542-553.	4.8	2
589	Pharmacological inhibitors of Î²-cell dysfunction and death as therapeutics for diabetes. Frontiers in Endocrinology, 0, 14, .	1.5	3
590	The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-ÎºB pathway. International Immunopharmacology, 2023, 117, 110028.	1.7	0
591	Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes. Therapeutic Advances in Chronic Disease, 2023, 14, 204062232311615.	1.1	2
592	Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology, 0, 14, .	1.5	3
593	A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity. Nature Communications, 2023, 14, .	5.8	5
594	The Effect of the Sodiumâ€"Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimerâ€™s Disease. Biomedicines, 2023, 11, 1025.	1.4	3
595	Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature Reviews Cardiology, 2023, 20, 463-474.	6.1	46
596	GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease. Postepy Higieny I Medycyny Doswiadczalnej, 2023, 77, 1-8.	0.1	0
597	In vitro comparison of whey protein isolate and hydrolysate for their effect on glucose homeostasis markers. Food and Function, 2023, 14, 4173-4182.	2.1	2
598	Intestinal <scp>ACE2</scp> regulates glucose metabolism in dietâ€induced obese mice through a novel gutâ€islet axis mediated by tryptophan. Obesity, 2023, 31, 1311-1325.	1.5	2
599	Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity. Clinical Science, 2023, 137, 663-678.	1.8	1
600	Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies. Biomedicines, 2023, 11, 1126.	1.4	9
601	Chitosan-Based Hybrid Dressing Materials for Treatment of Diabetic Wounds. Biological and Medical Physics Series, 2023, , 201-219.	0.3	1

#	Article	IF	Citations
602	The role of ChREBP in carbohydrate sensing and NAFLD development. Nature Reviews Endocrinology, 2023, 19, 336-349.	4.3	9
604	Trp-Tyr is a dipeptide structure that potently stimulates GLP-1 secretion in a murine enteroendocrine cell model, identified by comprehensive analysis. Biochemical and Biophysical Research Communications, 2023, 661, 28-33.	1.0	2
605	Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats. Brain Research, 2023, 1809, 148371.	1.1	1
606	Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. Frontiers in Medicine, 0, 10, .	1.2	3
607	Distinct Roles for Brain and Pancreas in Basal and Postprandial Glucose Homeostasis. Diabetes, 2023, 72, 547-556.	0.3	3
608	æ‘,é£Ÿèª¿ç¯€ã«ãŠã‘ã‚‹æ±,å¿ƒæ€§è¿·èµ°ç¥žçµŒã®å½¹å‰². Nihon EiyÅ•ShokuryÅ•Gakkai Shi = Nippon EiyÅ•ShokuryÅ•Gakkaishi = Journa Nutrition and Food Science, 2023, 76, 95-104.	0.2	1
609	Activation of Insulin Gene Expression via Transfection of a CRISPR/dCas9a System Using Magnetic Peptide-Imprinted Nanoparticles. Pharmaceutics, 2023, 15, 1311.	2.0	1
611	Elucidating the central anorexigenic mechanism of glucagon-like peptide 1 in Japanese quail (Coturnix) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	0
617	Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia, 2023, 66, 1796-1808.	2.9	20
634	Pancreatic Î²-cell heterogeneity in adult human islets and stem cell-derived islets. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	1
657	Neuropeptides Modulate Feeding via the Dopamine Reward Pathway. Neurochemical Research, 2023, 48, 2622-2643.	1.6	2
660	Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nature Metabolism, 2023, 5, 933-944.	5.1	15
662	Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?. Journal of Endocrinological Investigation, 2023, 46, 2213-2236.	1.8	2
668	GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?. Acta Diabetologica, 2023, 60, 1441-1448.	1.2	3
671	In silico tools to comprehend legumes-derived bioactive peptides in diabetes and hypertension therapeutics. , 2024, , 253-267.		0
677	The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia, 2023, 66, 1846-1858.	2.9	6
684	Incretins beyond type 2 diabetes. Diabetologia, 2023, 66, 1809-1819.	2.9	1
693	The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 784-796.	8.2	10

#	Article	IF	Citations
732	Pancreatic Î² cells: the metabolic network underlying bodyâ€™s glucostat. , 2024, , 181-197.		0
737	Pharmacological Strategies for Pediatric Obesity. , 2023, , 139-210.		0
739	Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	2
752	An overview of the anatomy, physiology, and pathology of pancreatic cancer. , 2024, , 3-13.		0
777	Gutâ€“brain interactions. , 2023, , .		0
789	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
791	Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduction and Targeted Therapy, 2024, 9, .	7.1	2
803	Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis. Endocrine, 2024, 84, 1-15.	1.1	0
804	Type 2 diabetes mellitus: Novel targets and multitarget-directed phytotherapy. , 2024, , 385-408.		0
805	Gut-Brain Axis Modulation of Metabolic Disorders: Exploring the Intertwined Neurohumoral Pathways and Therapeutic Prospects. Neurochemical Research, 2024, 49, 847-871.	1.6	0
808	Glucagon and the metabolic syndrome. , 2024, , 337-350.		0
814	A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches. Diabetes Therapy, 2024, 15, 585-609.	1.2	0
819	Current and future state of pharmacological management of pediatric obesity. International Journal of Obesity, 0, , .	1.6	0
823	A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology, 2024, 80, 669-676.	0.8	0